CIA
TXG icon

Cape Investment Advisory’s 10x Genomics TXG Stock Holding History

Cape Investment Advisory’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50
Closed -$718 – 1196
2024
Q4 		$718 Hold
50
– – ﹤0.01% 995
2024
Q3 		$1.13K Hold
50
– – ﹤0.01% 867
2024
Q2 		$973 Buy
+50
New +$1.31K ﹤0.01% 838

Other funds holding TXG

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cape Investment Advisory's TXG Position: Q1 2025 in Review

Cape Investment Advisory sold out of 10x Genomics (TXG) in Q1 2025, closing a stake of 50 shares — an estimated $718 sold.

Cape Investment Advisory first reported a position in TXG in Q2 2024 and held it in 3 quarters. The position peaked at $1.13K in Q3 2024. 274 funds tracked by Wall St. Rank hold TXG as of Q1 2025.

  • Cape Investment Advisory reported no remaining 10x Genomics position as of Q1 2025 after selling out during the quarter.
  • Cape Investment Advisory sold 50 10x Genomics shares in Q1 2025, an estimated $718.
  • Cape Investment Advisory first reported a position in 10x Genomics in Q2 2024 and held it in 3 quarters.
  • Cape Investment Advisory's 10x Genomics position peaked at $1.13K in Q3 2024.
  • 274 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2025.

Based on Cape Investment Advisory's 13F filing for Q1 2025, filed 16 May 2025.